icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
V6TqNyKW4sKWQ7eq